Clinical study of entecavir and adefovir dipivoxil in the treatment of decompensated cirrhosis of hepatitis B
10.3969/j.issn.1005-1678.2017.10.098
- VernacularTitle:恩替卡韦与阿德福韦酯治疗乙型病毒性肝炎失代偿性肝硬化的临床研究
- Author:
fan Qin LI
1
;
Da PAN
;
ming Li ZHU
Author Information
1. 温州市中心医院 消化内科
- Keywords:
entecavir;
adefovir dipivoxil;
decompensated hepatitis B;
decompensated cirrhosis;
clinical efficacy
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(10):229-230
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of entecavir and adefovir dipivoxil in the treatment of decompensated cirrhosis with hepatitis B virus. Methods 100 cases of decompensated cirrhosis of hepatitis B in our hospital (February 2015 to October 2016) were randomly divided into control group and experimental group, each with 50 cases. The control group was treated with adefovir dipivoxil, and the experimental group was treated with entecavir and adefovir dipivoxil. The clinical symptoms of the two groups were compared and analyzed. Results After treatment, the level of ALT in the experimental group was (46.20±3.21) U/L, and the level of AST was (52.40±3.90) U/L.The level of ALT in the control group was (70.43±10.90) U/L, and the level of AST was (70.33±9.19)U/L, and the two groups had statistical significance (P＜0.05). The negative rate of HBV-DNA in the experimental group was 76.0%, which was significantly higher than that in the control group (58.0%), and there was statistical difference (P＜0.05). The negative rate of HBeAg in the two groups was 22.0% and 24.0% respectively, and there was no significant
difference. Conclusion Entecavir and adefovir dipivoxil in the treatment of hepatitis B liver cirrhosis patients clinical effect is ideal,can significantly improve the liver function, improve clinical symptoms, high safety, has clinical significance.
